OKYO Pharma Limited
OTC: EMMLF0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Other OTC
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Gary S. Jacob
- Employees
- 7
- Headquarters
- London, United Kingdom
- IPO year
- 2020
- Market cap
- $22.7M
- Website
- https://www.okyopharma.com
Loading EMMLF…
Loading profile data…Frequently asked questions about EMMLF
What does OKYO Pharma Limited (EMMLF) do?
OKYO Pharma Limited is an early-stage biopharmaceutical company focused on developing therapies for individuals experiencing inflammatory eye conditions and ocular pain. A key asset in their pipeline is OK-101, specifically aimed at treating dry eye disease. Additionally, the company is advancing OK-201, which is a preclinical lipidated-peptide...
Where does EMMLF trade?
OKYO Pharma Limited (EMMLF) trades on the Other OTC.
What sector is EMMLF in?
OKYO Pharma Limited (EMMLF) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of OKYO Pharma Limited?
Gary S. Jacob is the chief executive officer of OKYO Pharma Limited (EMMLF).
Where is OKYO Pharma Limited headquartered?
OKYO Pharma Limited is headquartered in United Kingdom.
Does EMMLF pay a dividend?
OKYO Pharma Limited (EMMLF) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did EMMLF go public?
OKYO Pharma Limited (EMMLF) completed its initial public offering in 2020.